🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 30161Q104
- Market Cap
- Large Cap
- IPO
- 4/10/2000 · $13.00/share
Business: Exelixis, Inc., is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Exelixis has worldwide rights to cabozantinib, which they believe could have the potential to treat a wide variety of cancers. Exelixis was founded and incorporated in 1994. The company completed their initial public offering in April 2000. They are headquartered in South San Francisco, California, and their employees share a commitment to making a positive difference in the lives of patients with cancer and other serious diseases.
Company Contact
- CEO
- Michael M. Morrissey, Ph.D.
- CFO
- Christopher J. Senner
- Headquarters
- 1851 Harbor Bay Parkway, Alameda, CA 94502
- Phone
- 650-837-7000
- Fax
- 650-837-8205
- Investor Relations
- 650-837-8194 · shubbard@exelixis.com